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Summary
Heterogeneity in meta-analysis describes differences in treatment effects between trials that exceed those we may expect through chance alone.
Accounting for heterogeneity drives different statistical methods for summarizing data and, if heterogeneity is anticipated, a random-effects
model will be preferred to the fixed-effects model. Random-effects models assume that there may be different underlying true effects estimated
in each trial which are distributed about an overall mean. The confidence intervals (CIs) around the mean include both within-study and
between-study components of variance (uncertainty). Summary effects provide an estimation of the average treatment effect, and the CI depicts
the uncertainty around this estimate. There are 5 statistics that are computed to identify and quantify heterogeneity. They have different meaning
and give complementary information: Q statistic and its P-value simply test whether effect sizes depart from homogeneity, T2 and T quantify the
amount of heterogeneity, and I2 expresses the proportion of dispersion due to heterogeneity. The point estimate and CIs for random-effects
models describe the practical implications of the observed heterogeneity and may usefully be contrasted with the fixed-effects estimates.
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INTRODUCTION
Meta-analysis is the statistical synthesis of data from related stud-
ies, and the results summarize a body of research. Unlike the nar-
rative review, meta-analysis calculates a weighted average
treatment effect and its uncertainty [1]. The central unit of meta-
analysis is the treatment effect or effect size, which is a measure
of the relationship between 2 groups [2]. The effect size can vary
across related studies, and the principal goal of the synthesis is
the estimation of a summary effect, which is simply a weighted
mean of the individual effects. It is also critical to evaluate the ro-
bustness of the summary effect, including some expectation on
variability among studies and subsequently quantifying it. The
observed dispersion of the estimated effect sizes is partly spuri-
ous as it always includes a random (or sampling) error inherent
in each study, but it may also include a true variation of the effect
sizes in each study, namely heterogeneity.
Heterogeneity is the true difference in effect sizes related to in-
trinsic factors of the studies included in the meta-analysis [2, 3].
Differences in the characteristics of cohorts and in treatment
options, together with other reasons, lead to assume that studies
will not share a common effect size but will have heterogeneous
underlying effects. This assumption on heterogeneity is a critical
point when conducting a meta-analysis as it drives different
statistical methods for summarizing data and also different inter-
pretation of results. If our understanding is that all studies share
the same common effect, we will choose a fixed-effects model;
otherwise, if heterogeneity is expected, a random-effects model
will be preferred (Fig. 1) [3].
Fixed-effects model
The fixed-effects model assumes that all studies considered in the
meta-analysis share the same common true effect size (hence, the
term fixed) (Fig. 1A). Differences among observed effects are related
to sampling error (ei; i stands for study i), and factors influencing
the effect size are assumed to be the same in all the studies. There
is no heterogeneity (fi = 0) and the variance is completely due to
spurious dispersion (within-study variance). The summary effect is
the estimate of a common true effect, and the confidence intervals
(CIs) depict the uncertainty around this estimate.
Random-effects model
Random-effects models assume that there are different underly-
ing true effects. These true effect sizes are distributed about some
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mean (Fig. 1B) and can be considered as a random sample from
a distribution (usually Gaussian)—hence, the term random.
Random-effects models are preferred when study cohorts are
expected to be different or treatment options are not identical
among studies. The variance is accounted by both spurious
(within-study variance, i) and real dispersion (between-study
variance, fi), and a formula is applied to partition it into these 2
components, as the main focus shifts from the summary effect to
the identification and quantification of heterogeneity. Summary
effects provide an estimation of the average treatment effect, and
the CI depicts the uncertainty around this estimate, including the
component of heterogeneity [2]. In the presence of heterogene-
ity, the relative weights are more balanced than those assigned
under fixed effects as standard random-effects methods add a
common component of variance to each study weight to ac-
count for between study variability in treatment effects.
Consequently, this double source of variability (within and be-
tween study) will lead to wider variance, standard error and CI
for the summary effect [2].
For example, we can suppose to conduct a meta-analysis of
randomized controlled trials comparing clinical outcomes (30-
day mortality and 30-day pacemaker implantation) of adult
patients with severe aortic stenosis undergoing either transcath-
eter aortic valve implantation (TAVI) or surgical aortic valve re-
placement. Effect sizes can be hypothesized not to be identical
across studies as different risk profiles are included and also as
different devices were employed. Hence, random-effects model
would be preferred.
METHODOLOGY
Under the random-effects model, attention is focused on quanti-
fying heterogeneity and understanding its implications [2].
Specific methodologies are employed to partition the total dis-
persion, isolate the true variance and give an array of statistics for
abstracting the interpretation of results (Fig. 2).
Q statistic (also known as Cochrane’s Q)
Q statistic (also known as Cochrane’s Q) is the weighted sum of
squares; more easily, a measure of the total observed dispersion of
the estimated effect sizes. It is a standardized value, and it is not af-
fected by the metric of the effect size; hence, it is not a measure of
dispersion on the same scale of the effect size (not comparable).
Q  degrees of freedom
Q - df is the part of dispersion related to differences in the true
effects (heterogeneity or excess variation). It is calculated by sub-
tracting to Q the degrees of freedom (df), which represents the
within-study error. It is also a standardized measure.
Test for assumption of homogeneity
Test for assumption of homogeneity is based on Q statistics and
tests the null hypothesis that all studies share a common effect
size. The test performs badly in the small sample setting, and the
results are sensitive to the excess of dispersion and the number
of studies included as increase of dispersion moves towards sig-
nificance and an increased number of studies strengthen the evi-
dence of the test. To be noted, a significant P-value confirms that
the true effects vary while a non-significant P-value should be
discussed as it depends not only on the robustness of effect sizes
but it can also account for low power (small number of studies,
wide within study variance). Moreover, the homogeneity test, as
well as the Q statistic, cannot be employed as an estimate of the
amount of heterogeneity, and it simply tests the null hypothesis
that all effect sizes are consistent.
T2 and T-estimates of the variance and standard
deviation of the true effect sizes
T2 is the estimate of the variance of the true effect sizes (s2), de-
rived from the observed effects. Different from Q, it is expressed
Figure 1: Schematic diagram of the assumption of fixed- and random-effects models. In the fixed-effects model, there is no heterogeneity and the variance is
completely due to spurious dispersion. Summary effect is the estimate of the true effect (l). In the random-effects model, the true effect sizes are different and conse-
quently there is between-studies variance. The summary effect is the estimate of the mean of the distribution of the true effect sizes with an estimated variance of T2.
RD: risk difference.
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in the same metric of the summary effect, and it represents the
amount of true dispersion of the effect sizes. The most common
method for estimating the between-studies variance in a meta-
analysis is the DerSimonian–Laird estimator [4], which is based
on the method of moments and may be biased in some settings.
T is the square root of T2 and represents the estimate of standard
deviation of the normal distribution (s) of the true effect sizes. It
has the same metric of the summary effect. Assuming a normal
distribution of the true effect sizes, it can be used to describe the
distribution of the effects around their mean, calculating the 95%
CI of the summary effect. Increasing T-values reflect the in-
creased true variance around the mean in the summary estimate.
The I2 statistic expresses the proportion of the total dispersion
that accounts for true dispersion being the ratio between the ex-
cess of dispersion and total dispersion. It is calculated on Q, and
hence it is not the estimate of an underlying amount but only a
descriptive statistic. It is a measure of inconsistency among the
findings of the studies, and it is not affected by the number of
studies included in the meta-analysis. It was suggested that 25%,
50% and 75% could be considered low, intermediate and high in-
consistency, respectively [5]; nonetheless, these cut-offs are sim-
ply thresholds of crude guidelines and the evaluation of I2
statistic should overcome them.
In summary, there are 5 statistics that are computed to identify
and quantify heterogeneity. They have different meanings and
give complementary information: Q statistic and its P-value sim-
ply test whether effect sizes are homogeneous, T2 and T quantify
the amount of heterogeneity, and I2 expresses the proportion of
dispersion due to heterogeneity. A sixth, and potentially much
more useful, statistic describing the effects of heterogeneity is the
random-effects estimator of the pooled treatment effects.
Common statistical software and languages have functions to
estimate heterogeneity. Fixed- and random-effects meta-analyses
can be implemented in the R packages ‘Meta’, ‘metafor’, ‘rmeta’
and ‘epiR’. A tutorial for conducting meta-analysis with R with
the package ‘metaphor’ is described by Viechtbauer [6]. RevMan
5 is the software developed for preparing and maintaining
Cochrane Reviews, and it is possible to choose random- or fixed-
effects models while conducting meta-analysis. Macros for con-
ducting meta-analysis in SPSS can be found in the web (e.g.
http://mason.gmu.edu/dwilsonb/ma.html). In Stata, Meta and
Metan commands have been developed to generate fixed- and
random-effects meta-analysis. The %METAANAL macro is an SAS
version 9 macro that produces the DerSimonian–Laird estimators
for random- or fixed-effects model.
REPORTING
Meta-analysis should be reported following published guidelines,
such as PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) and MOOSE (Meta-analysis of
Observational Studies in Epidemiology) [7, 8].
Authors should explicitly state the rationale for the choice of
the model, underscoring potential sources of variability of the
studies included in the meta-analysis. In the results and/or in the
forest plot, the evaluation of heterogeneity should be reported,
including the Q statistics, the test for assumption of homogeneity,
the I2 statistic and the estimate of the variance of the true effect
sizes T2. The random-effects estimator and CIs describe the im-
portance of heterogeneity in the practical setting. In the discus-
sion, authors should make inference not only on the summary
effect but also on the dispersion.
Figure 2: A flowchart of the array of statistics for abstracting the interpretation of results.
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There are some notes to keep in mind. First, a very small num-
ber of studies can lead to a poor estimate of heterogeneity.
Hence, the random-effects model has been correctly chosen but
there is insufficient information for applying it. In this case, one
possible option could be to avoid reporting a summary effect as
conclusions on effect size and its CI cannot be drawn, or an alter-
native could be represented by a different approach, such as a
Bayesian one, where the extent of heterogeneity maybe inferred
through an informative prior. Moreover, the practice of performing
a fixed-effects model and subsequently moving to the random-
effects model if the test of homogeneity is significant should be
discouraged as the choice should be based on hypothesis on
common effect sizes and not on a statistical test that often suffers
of low power. Differences in the characteristics of cohorts (e.g.
different preoperative risk profiles) and in treatments options
(such as different devices with potential implementation of inter-
ventions), together with other reasons (different ethnicity, geo-
graphical variation, etc.), lead to assume that studies will not
share a common effect size and should be analysed with the ran-
dom-effects model. Further, the standard methods for random
effects (DerSimonian and Llaird) include a component of vari-
ance to describe the between-study variability adaptively, diverg-
ing from the fixed-effects model when the P-value for
heterogeneity is significant. If the random-effects model is cho-
sen and T2 was demonstrated to be 0, it reduces directly to the
fixed effect, while a significant homogeneity test in a fixed-effect
model leads to reconsider the motivations at its basis. However,
the contrast of the fixed- and random-effects results provides a
useful description of the importance of heterogeneity in the
results. Finally, the interpretation of random-effects meta-analysis
can be implemented by a prediction interval, which is a measure
that provides a predicted range for the true treatment effect in
an individual study [3]. It resembles reference ranges usually
employed in other areas of medicine, such as those for blood
pressure or birth weight across the population [3].
EXAMPLE
We can aim to meta-analyse randomized controlled trials compar-
ing 30-day mortality and 30-day pacemaker implantation of adult
patients with severe aortic stenosis undergoing either TAVI or sur-
gical aortic valve replacement. We choose to evaluate the risk dif-
ference of outcomes between treatment and control groups. The 7
included trials differ in the perioperative risk profiles, as [9, 10] are
performed in intermediate-risk, whereas [11–14] have been per-
formed in high-risk patients. Moreover, treatment options are also
different because different TAVI devices have been employed
across studies [9–14]. These considerations can lead to assume that
heterogeneity (between study differences in treatment effects) is
anticipated and the random-effects model is preferred.
The analysis of heterogeneity for 30-day mortality demonstrates
that trials are homogeneous (Fig. 3A), being the test for assumption
of homogeneity (see Methodology section) P-value = 0.50 and
the percentage of heterogeneity on total variability (I2) of 0%,
suggesting that the variability in study estimates is entirely due to
chance. The estimate of the variance of the true effect sizes (T2)
is 0. In this case with no source of heterogeneity and only within-
study variance, the random-effects model coincides with the
fixed-effects model, as shown in Fig. 4A, and the summary risk
difference (-0.009; 95% CI -0.0191 and 0.0011) is the estimate of
a common true effect size. The point estimate thus suggests that
average mortality under TAVI is 0.9% lower than under surgical
aortic valve replacement, but the 95% CIs include a reduction of
1.9% or an increase of 0.1%.
The analysis of heterogeneity for 30-day pacemaker implanta-
tion shows significant heterogeneity across studies with the test
for assumption of homogeneity with P-value <0.0001 (Fig. 3B)
and high inconsistency (I2 96.16%). The estimate of the variance
of the true effect sizes (T2) is 0.0094. The summary risk difference
(0.11; 95% CI 0.03–0.19) is the estimation of the mean of the dis-
tribution of the effects. As the CI does not contain zero, there is
Figure 3: Random-effects meta-analysis of 6 trials that examine the effect of TAVR versus surgical aortic valve replacement on 30-day incidence of mortality (A) and
pacemaker implantation (B). In the forest plot for 30-day mortality, there is no heterogeneity and the random-effects analysis reduces to fixed-effects analysis.
(B) Heterogeneity is significant and the summary effect is an estimate of the true effect sizes. df: degrees of freedom.
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good evidence that on average TAVI is related to the increased in-
cidence of 30-day pacemaker implantation. Figure 4B shows the
implication of model choice; in random effect, the relative weights
are more balanced and the double source of variability led to
wider variance, standard error and CI for the summary effect.
CONCLUSIONS
In summary, heterogeneity assessment is an important step in
meta-analysis as in many cases the assumption of the same true
effect across studies is implausible. Thus random-effects meta-
analysis, which accounts for unexplained heterogeneity, will con-
tinue to be prominent in the medical literature [3].
Conflict of interest: none declared.
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Figure 4: Comparison between random- and fixed-effects models in the example. Both fixed- and random-effects models were applied to the example in order to un-
derscore the differences on estimation. The fixed-effects model is reported in red, and the random-effects model is depicted in black. (A) There is coincidence be-
tween the 2 models, as heterogeneity is null and the random-effects model is reduced to the fixed-effects model. In the second outcome (B), there is a significant
heterogeneity and hence different estimates are obtained by applying fixed- or random-effects model, as fixed-effects model does not consider the between-studies
variance, and summary estimate is performed by forcing T2 = 0, although it is significant (red). The appropriate choice of random-effects model (black) leads to more
balanced relative weights and to wider variance, standard error and confidence interval for the summary risk difference.
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